BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.
| Ticker |
Sentiment |
Impact |
|
VCYT
|
Neutral
|
20 %
|
|
BIO
|
Neutral
|
29 %
|
|
HQY
|
Neutral
|
20 %
|
|
PAHC
|
Neutral
|
20 %
|
